Primary Category:
Treatment Protocols
Disease Category:
Diffuse Large B-cell Lymphoma, Lymphoma, Non-Hodgkin Lymphoma
Status:
Closed
Randomized Phase II/III Study of Venetoclax (ABT199) Plus Chemoimmunotherapy for MYC/BCL2 Double-Hit and Double Expressing Lymphomas
NCT#03984448
A051701 is closed to accrual, effective December 14, 2023.
